KT&G and PMI Extend Global E-cigarette Collaboration

Jan.30.2023
KT&G and PMI Extend Global E-cigarette Collaboration
KT&G and PMI renewed a 15-year contract to sell their non-combustible products globally, helping with KT&G's overseas market position.

According to a report by Yonhap News Agency on January 30th, Korea Tobacco & Ginseng Corporation (KT&G) and Philip Morris International (PMI) have extended a supply contract for 15 years. KT&G will distribute its three types of non-burning heated products through PMI's global sales network, except in South Korea.


The products include the Lil Solid, Lil Hybrid, and Lil Aible devices, as well as their corresponding proprietary pods named Fiit, Miix, and Aiim.


During a press conference, KT&G CEO Baek Bok-in stated that this collaboration will help strengthen KT&G's position for smokeless products in international markets. The extension of the three-year strategic agreement signed with PMI in 2020 will also lay the foundation for stable growth in their global business.


KT&G Corporation recently announced during an investor event that it aims to double its sales by 2027, reaching a total of 10 trillion Korean won (approximately $8.1 billion USD). The company plans to obtain more than half of these revenues from their overseas businesses, while also strengthening their next-generation product (NGP) division, which includes heated non-burning (HnB) products and functional health foods.


According to reports, 90% of KT&G's current revenue comes from cigarette sales and the remaining 10% comes from their HnB products. The company has four tobacco manufacturing plants located in South Korea, Russia, Turkey, and Indonesia with a yearly production capacity of 13.6 billion units. Since signing an agreement with Philip Morris International in 2020, KT&G has expanded the export of their HnB products to over 30 countries.


Sources:


KT&G has set a goal of generating 50% of its sales from overseas markets by 2027.


KT&G and PMI have extended their partnership to expand their presence in global markets with e-cigarettes.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

FDA Details Carcinogenicity Tiering and ELCR Framework as Small Manufacturers Press for Predictability
FDA Details Carcinogenicity Tiering and ELCR Framework as Small Manufacturers Press for Predictability
During the “Toxicological Profile” session at FDA’s Feb 10 PMTA roundtable, officials outlined the carcinogenicity tiering system and Excess Lifetime Cancer Risk (ELCR) framework used in ENDS reviews under the APPH standard. Small manufacturers questioned database transparency, exposure assumptions, and the existence of clear compliance benchmarks. FDA reiterated toxicological risk is assessed case by case within a broader population-level determination.
Feb.11
IQOS UK unveils 2026 pop-up events plan, first stops set for London and three other cities
IQOS UK unveils 2026 pop-up events plan, first stops set for London and three other cities
IQOS’ UK website shows the company will roll out time-limited pop-up experience spaces across Britain in 2026 for adult consumers. The first confirmed locations are London, the West Midlands area near Birmingham, Manchester and Romford, offering product demonstrations, pop-up-only promotions and nicotine pouch sampling. Entry will be restricted to those aged 18 and over, with “Challenge 25” ID checks in place.
Feb.03 by 2FIRSTS.ai
PMI Launches Mass Production of ZYN at $600M Aurora Manufacturing Hub
PMI Launches Mass Production of ZYN at $600M Aurora Manufacturing Hub
Philip Morris International (PMI), through its subsidiary Swedish Match, has started large-scale production at a 600,000-square-foot ZYN nicotine pouch facility in Aurora, Colorado. The $600 million investment makes the site one of three ZYN manufacturing plants in the United States and the company’s second U.S. facility after Owensboro, Kentucky.
PMI
Feb.21
FDA Outlines Manufacturing Requirements as Critical to ENDS PMTA Success
FDA Outlines Manufacturing Requirements as Critical to ENDS PMTA Success
FDA officials said manufacturing consistency is a core prerequisite for ENDS PMTA reviews, not a procedural formality. During its February 10, 2026 roundtable, the agency outlined expectations for quality management systems, manufacturing documentation, nicotine control, stability studies, and risk mitigation, emphasizing that robust manufacturing evidence underpins determinations of whether products are appropriate for the protection of public health.
Feb.11
The Volume Illusion: Measuring the Future of Nicotine with the Tools of the Past
The Volume Illusion: Measuring the Future of Nicotine with the Tools of the Past
As next-generation nicotine products become economically central rather than marginal, traditional volume-based metrics are increasingly unable to explain consumption, risk, and value. Units designed for a cigarette-based economy struggle to describe systems defined by delivery speed, pharmacokinetics, and adaptive user behavior. Drawing on financial reporting, regulation, and nicotine science, a fundamental question: can the future of nicotine still be measured using the tools of its past?
Feb.09 by Alan Zhao | 2Firsts Perspectives
PMTA Roundtable Opens with Industry Questioning Product Characterization Standards, FDA Defends Regulatory Boundaries
PMTA Roundtable Opens with Industry Questioning Product Characterization Standards, FDA Defends Regulatory Boundaries
At the opening of FDA’s PMTA roundtable, small ENDS manufacturers warned that unclear product characterization standards are limiting their ability to invest and raise capital. FDA officials acknowledged industry concerns but said regulatory flexibility is constrained by statutory and procedural boundaries.
Feb.11